SKYE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

New York, NY – On November 22, 2025, the national securities‑law firm Faruqi & Faruqi, LLP announced that it is investigating potential claims on behalf of investors in Skye Bioscience, Inc. (NYSE: SKYE). According to the firm, the investigation concerns whether Skye and its executives violated federal securities laws by making false or misleading statements and/or failing to disclose material information. Specifically, the complaint alleges that: (1) Skye’s investigational drug nimacimab was less effective than the company represented; (2) its clinical, regulatory and commercial prospects were overstated; and (3) as a result, the company’s public statements were materially false and misleading during the relevant period. The trigger for the investigation came when on October 6, 2025, Skye released topline data from its 26‑week Phase 2a “CBeyond™” proof‑of‑concept study of nimacimab. The release revealed that the monotherapy arm did not achieve the primary endpoint of weight loss versus placebo, and that preliminary pharmacokinetic analysis showed lower‑than‑expected drug exposure, indicating a potential need for higher dosing. This disclosure caused Skye’s stock to plunge approximately 60%, falling $2.85 per share to close at $1.90. Investors who purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025 may be eligible to participate. The firm reminds investors of the January 16, 2026 deadline to seek appointment as lead plaintiff in the class action. Faruqi & Faruqi also encourages anyone with information regarding Skye’s conduct—including whistleblowers, former employees and shareholders—to contact the firm. #SkyeBioscience #Nimacimab #SecuritiesLitigation #InvestorAlert #SlimScan #GrowthStocks #CANSLIM